-logo.webp "TRAJENTA (linagliptin) logo"){kind=logo}
TRAJENTA®
Linagliptin
Product Overview
The simplicity of one dose, once daily to help lower HbA1c in your adult T2D patients.1
TRAJENTA® contains the active ingredient linagliptin, which is a dipeptidyl peptidase-4 inhibitor (DPP-4i).1 TRAJENTA® is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as:1
- monotherapy when it is not appropriate to use metformin due to intolerance or contraindication as the result of renal impairment
- combination therapy when other products, including insulin alone or in combination with metformin, do not provide sufficient glycaemic control
See SmPC for available information on different combinations.
Product key facts
Indications
Type 2 diabetes mellitis in adults
Active ingredient
Linagliptin
Legal category
Prescription only medicine
Concentration
5 mg once a day
Administration form
Oral
Dosage form
Film-coated tablet
Pack sizes
Perforated alu/alu unit dose blisters in cartons containing 10 x 1, 14 x 1,28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1, 90 x 1, 98 x 1, 100 x 1 and 120 x 1 film-coated tablets.
Not all pack sizes may be marketed
Simple dosing for a broad range of adult patients
Dosing for TRAJENTA® provides unique simplicity-always 5 mg once daily, independent of age,1 BMI,1 ethnicity,1 background T2D therapy,1† disease duration,2 hepatic function,1* and renal function.1
A broad range of adults with T2D§ can benefit from TRAJENTA®
In phase III clinical trials, TRAJENTA® produced clinically significant improvements in glycaemic control,3,4 regardless of renal function,4,5 and patient age.6
Proven safety and efficacy across two CVOTs
In CARMELINA® and CAROLINA®, which included over 13,000 patients, TRAJENTA® demonstrated a safety profile across a broad range of T2D patients.7-10#
Footnotes
- * Pharmacokinetic studies suggest that no dose adjustment is required for patients with hepatic impairment but clinical experience in such patients is lacking (TRAJENTA® SmPC).
- †Sulphonylureas and insulin are known to cause hypoglycaemia. Therefore, caution is advised when linagliptin is used in combination with a sulphonylurea and/or insulin. A dose reduction of the sulphonylurea or insulin may be considered (TRAJENTA® SmPC).
- #CARMELINA® and CAROLINA® included 6,979 and 6,033 patients respectively.
- §TRAJENTA® is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as: monotherapy, when metformin is inappropriate due to intolerance, or contraindicated due to renal impairment; combination therapy, in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.
References
- TRAJENTA® (linagliptin) Summary of Product Characteristics. SmPCs available at EMC: www.medicines.org.uk (GB) and https://www.emcmedicines.com/en-GB/northernireland/ (NI).
- Lajara R, et al. Clin Ther. 2014;36(11):1595-605.
- Del Prato S, et al. J Diab Compl. 2013;27:274–9.
- Cooper M, et al. Poster No. 1068-P. The 71st Scientific Sessions of the American Diabetes Association, 24–28 June 2011, San Diego, CA, USA.
- McGill JB, et al. Diabetes Care. 2013;36:237-44.
- Patel S, et al. European Association for the Study of Diabetes 2011, 12-16 September 2011, Lisbon, Portugal; Poster P832.
- Rosenstock J, et al. Cardiovasc Diabetol. 2018;17:39.
- Rosenstock J, et al. JAMA 2019; 321(1):69-79.
- Marx N, et al. Diab Vasc Res. 2015; 12:164-74.
- Rosenstock J, et al. JAMA. 2019;322(12):1155–1166.
PC-GB-105686 V2
September 2022